ストックスクリーナーアプリを入手
41.83
1.31%
0.54
前日終値:
$41.29
開ける：
$41.3
24時間の取引高:
5.61M
Relative Volume:
2.85
時価総額：
$4.94B
収益：
$1.29B
当期純損益:
$251.00M
株価収益率:
21.19
EPS:
1.9744
ネットキャッシュフロー:
$-193.86M
1週間 パフォーマンス:
+9.22%
1か月 パフォーマンス:
+10.63%
6か月 パフォーマンス:
+15.52%
1年 パフォーマンス:
+205.55%
1日の値動き範囲:
$41.01
$42.81
1週間の範囲:
$37.64
$42.81
52週間の値動き範囲:
$13.47
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
41.83 | 4.94B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.09 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
542.66 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny - Ad-hoc-news.de
INDV Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Indivior Pharmaceuticals, Inc. Actuals & Estimates (LS:A42086) - TradingView
Indivior Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INDV) - TradingView
Is Big Pharma's Patent Cliff Driving a New M&A Wave - Kavout | AI
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
E7P Forecast — Price Target — Prediction for 2027 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
Reasons Why Investors Should Consider Betting on Indivior Stock - The Globe and Mail
A42086 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Australia
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior gains new overweight at Barclays on business turnaround - MSN
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Indivior (INDV) 10K Form and Latest SEC Filings 2026 - MarketBeat
Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds - Sahm
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
INDIVIOR PHARMACEUTICALS INC (INDV) Stock Chart - ChartMill
Indivior stock gains new Overweight at Barclays (INDV:NASDAQ) - Seeking Alpha
Barclays Initiates Indivior at Overweight With $46 Price Target - marketscreener.com
Indivior PLC (INDV) Institutional Confidence - TradingKey
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
How Strong SUBLOCADE Uptake And A $175M Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Suboxone Tooth Decay Lawsuit Updates for 2026 - Lawsuit Information Center
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
INDV Stock: What Sublocade Growth Signals for 2026 - The Globe and Mail
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026 - Yahoo Finance
Is Indivior Stock a Buy After Higher 2026 Guidance? - Yahoo Finance
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - The Globe and Mail
[144] Indivior Pharmaceuticals, Inc. SEC Filing - Stock Titan
A Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price Gains - Yahoo Finance
Indivior CFO Ryan Preblick sells $1.36m in company stock By Investing.com - Investing.com Australia
Indivior Pharmaceuticals Inc (INDV) CFO Ryan Preblick Sells 36,0 - GuruFocus
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
Indivior CFO Ryan Preblick sells $1.36m in company stock - Investing.com
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
4.26%
0.13%
大文字化:
|
ボリューム (24 時間):